Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | EIF2AK4 | Q9P2K8 | 17/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991785 | 0.83 | JAK2 (0.44) | EIF2AK4 | |
| SCHEMBL21194429 | 0.80 | EIF2AK4 (0.59) | EIF2AK4 | |
| SCHEMBL1993988 | 0.80 | EIF2AK4 (0.48) | EIF2AK4 | |
| SCHEMBL12615931 | 0.77 | EIF2AK4 (0.41) | EIF2AK4 | |
| SCHEMBL1995553 | 0.77 | KIT (0.53) | — | |
| SCHEMBL20125086 | 0.72 | CYP1A2 (0.46) | CYP1A2CYP2C9EIF2AK4ALDH1A1HPGD | |
| SCHEMBL12998305 | 0.71 | CHEK1 (0.54) | CYP1A2CYP2C9ALDH1A1HPGDKDM4E | |
| SCHEMBL21208229 | 0.69 | EIF2AK4 (0.61) | EIF2AK4 | |
| SCHEMBL12998304 | 0.68 | GABRG2 (0.54) | KDM4EGAA | |
| SCHEMBL21194181 | 0.68 | EIF2AK4 (0.55) | EIF2AK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CYP1A2 3059/4885CYP2C9 3064/4885EIF2AK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.